Premium
Near real‐time vaccine safety surveillance with partially accrued data
Author(s) -
Greene Sharon K.,
Kulldorff Martin,
Yin Ruihua,
Yih W. Katherine,
Lieu Tracy A.,
Weintraub Eric S.,
Lee Grace M.
Publication year - 2011
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2133
Subject(s) - medicine , vaccine safety , postmarketing surveillance , pharmacoepidemiology , safety monitoring , virology , immunology , pharmacology , adverse effect , bioinformatics , immunization , antigen , medical prescription , biology
Purpose The Vaccine Safety Datalink (VSD) Project conducts near real‐time vaccine safety surveillance using sequential analytic methods. Timely surveillance is critical in identifying potential safety problems and preventing additional exposure before most vaccines are administered. For vaccines that are administered during a short period, such as influenza vaccines, timeliness can be improved by undertaking analyses while risk windows following vaccination are ongoing and by accommodating predictable and unpredictable data accrual delays. We describe practical solutions to these challenges, which were adopted by the VSD Project during pandemic and seasonal influenza vaccine safety surveillance in 2009/2010. Methods Adjustments were made to two sequential analytic approaches. The Poisson‐based approach compared the number of pre‐defined adverse events observed following vaccination with the number expected using historical data. The expected number was adjusted for the proportion of the risk window elapsed and the proportion of inpatient data estimated to have accrued. The binomial‐based approach used a self‐controlled design, comparing the observed numbers of events in risk versus comparison windows. Events were included in analysis only if they occurred during a week that had already passed for both windows. Results Analyzing data before risk windows fully elapsed improved the timeliness of safety surveillance. Adjustments for data accrual lags were tailored to each data source and avoided biasing analyses away from detecting a potential safety problem, particularly early during surveillance. Conclusions The timeliness of vaccine and drug safety surveillance can be improved by properly accounting for partially elapsed windows and data accrual delays. Copyright © 2011 John Wiley & Sons, Ltd.